AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $1,130.51
- 52-wk high
- $1,292.65
- High
- $1,131.44
- 52-wk low
- $707.59
- Low
- $1,113.29
- Prev close
- $1,123.00
- Mkt cap
- $1.00T
- P/E
- 37.7x
- Volume
- 1.84M
- Fwd P/E
- 23.8x
- Beta
- 0.50
- Div yield
- 0.57%
- P/S
- 12.6x
- P/B
- 29.6x
- Profit margin
- +33.5%
- Op margin
- +54.2%
- ROE
- +102.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 39.4% above what analysts expected.
Earnings per share
$6.01 expected
GAAP EPS was $7.94 and adjusted EPS was $8.38. The analyst basis could not be confirmed, so no beat or miss is shown.
FY2026 guidance
$85.00B to $87.00B
No comparable estimate
Reports Oct 29, 2026, in 47 days
EPS expected
$8.95 to $11.30
Revenue expected
15 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.60B | $19.29B | $19.80B | $22.97B |
| Cost of what it sold | $3.01B | $2.88B | $3.58B | $3.27B |
| Gross profit | $14.59B | $16.41B | $16.22B | $19.71B |
| What it spent | ||||
| Research and development | $3.47B | $3.80B | $3.51B | $3.82B |
| Sales and admin | $2.74B | $3.34B | $2.93B | $3.43B |
| Other operating costs | — | $487.5M | $928.0M | $3.48B |
| Total operating expenses | $6.21B | $7.63B | $7.37B | $10.73B |
| What was left | ||||
| Operating profit | $8.39B | $8.78B | $8.85B | $8.98B |
| Interest on debt | $179.6M | $123.0M | $332.0M | $345.0M |
| Profit before tax | $7.23B | $8.27B | $8.85B | $9.25B |
| Tax | $1.65B | $1.63B | $1.45B | $2.15B |
| Net profit | $5.58B | $6.64B | $7.40B | $7.09B |
| EBITDA | $7.88B | $8.39B | $9.69B | $9.25B |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
7,741 Shares in Merck & Co., Inc. $MRK Bought by Talon Private Wealth LLC
Leans bearishSep 12Smith Chas P & Associates PA Cpas Has $46.21 Million Stake in Merck & Co., Inc. $MRK
Leans bearishSep 11Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential
NeutralSep 11Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
NeutralSep 11The Manufacturers Life Insurance Company Has $266.40 Million Position in Merck & Co., Inc. $MRK
NeutralSep 11Morgan Stanley cuts Novo Nordisk on growth, patent cliff concerns; shares dip
NeutralSep 11Allworth Financial LP Cuts Stock Holdings in CVS Health Corporation $CVS
Leans bullishSep 11ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com
Leans bearishSep 10
Macro
30 macro signals shaping LLY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results